Announced Thu, 3 Sept, 2026 · 20:06 IST
Cipla partners with Qilu for US biosimilar to Keytruda
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.4%1-day move
₹1389.90
prior close
₹1397.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.8-1.2-1.4+0.4-0.4-1.9-1.2-1.7-2.3-0.4-3.9——
Up moveDown movePending
AI summary
Cipla's US arm will exclusively commercialize QL2107, a biosimilar to MSD's blockbuster cancer drug Keytruda, in the United States. Chinese partner Qilu will handle development, regulatory registration, and supply. The deal strengthens Cipla's oncology biosimilar portfolio and US presence, though financial terms were not disclosed.
Likely market impact
Expands Cipla's US biosimilar and oncology pipeline. No financial terms shared, so near-term revenue impact uncertain. Positive long-term growth signal.